Literature DB >> 11846494

Chlamydia pneumoniae IgA titres and coronary heart disease; prospective study and meta-analysis.

J Danesh1, P Whincup, S Lewington, M Walker, L Lennon, A Thomson, Y-K Wong, X Zhou, M Ward.   

Abstract

AIMS: To examine associations between Chlamydia pneumoniae IgA titres and incident coronary heart disease, and to compare them with associations previously reported between C. pneumoniae IgG titres and coronary heart disease. METHODS AND
RESULTS: We measured serum concentrations of C. pneumoniae IgA antibodies in 502 coronary heart disease cases and in 1005 age- and town-matched controls 'nested' in a community-based prospective study of 5661 British men (mean follow-up in controls, 16 years), and conducted a meta-analysis of published prospective studies to place our findings in context. Two hundred and twenty-one (44%) of the cases were in the top third of C. pneumoniae IgA titres compared with 336 (33%) of the controls, yielding an odds ratio for coronary heart disease of 1.84 (95% confidence interval 1.40-2.43) which was largely unchanged after adjustment. In aggregate, the present study and nine previously reported prospective studies of C. pneumoniae IgA titres involved 2283 cases, yielding a combined odds ratio for coronary heart disease of 1.25 (1.03-1.53), with no significant heterogeneity among the ten studies (chi(2)9=7.8; P>0.1). This combined odds ratio is compatible with that previously reported for C. pneumoniae IgG titres and coronary heart disease (1.15, 0.97-1.36).
CONCLUSION: Neither C. pneumoniae IgA titres nor IgG titres are strongly predictive of coronary heart disease in the general population. Copyright 2001 The European Society of Cardiology.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11846494     DOI: 10.1053/euhj.2001.2801

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  21 in total

1.  Interlaboratory reliability of microimmunofluorescence test for measurement of Chlamydia pneumoniae-specific immunoglobulin A and G antibody titers.

Authors:  Alyson J Littman; Lisa A Jackson; Emily White; Mark D Thornquist; Charlotte A Gaydos; Thomas L Vaughan
Journal:  Clin Diagn Lab Immunol       Date:  2004-05

2.  Circulatory disease mortality in the Massachusetts tuberculosis fluoroscopy cohort study.

Authors:  Mark P Little; Lydia B Zablotska; Alina V Brenner; Steven E Lipshultz
Journal:  Eur J Epidemiol       Date:  2015-08-09       Impact factor: 8.082

3.  Chlamydia pneumoniae enhances cytokine-stimulated human monocyte matrix metalloproteinases through a prostaglandin E2-dependent mechanism.

Authors:  Min P Kim; Charlotte A Gaydos; Billie Jo Wood; Justin P Hardick; Yahong Zhang; Larry M Wahl
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

Review 4.  A review of non-cancer effects, especially circulatory and ocular diseases.

Authors:  Mark P Little
Journal:  Radiat Environ Biophys       Date:  2013-08-01       Impact factor: 1.925

5.  Chlamydia pneumoniae and Helicobacter pylori IgG seropositivities are not predictors of osteoporosis-associated bone loss: a prospective cohort study.

Authors:  Mohammad Reza Kalantarhormozi; Majid Assadi; Katayoun Vahdat; Kamyar Asadipooya; Afshin Ostovar; Katayoun Raissi; Hossein Darabi; Shokrollah Farrokhi; Sina Dobaradaran; Maryam Farrokhnia; Iraj Nabipour
Journal:  J Bone Miner Metab       Date:  2015-06-09       Impact factor: 2.626

6.  Salivary immunoglobulins and prevalent coronary artery disease.

Authors:  S Janket; J H Meurman; A E Baird; M Qvarnström; P Nuutinen; L K Ackerson; J Hong; P Muthukrishnan; T E Van Dyke
Journal:  J Dent Res       Date:  2010-02-22       Impact factor: 6.116

7.  Immunohistostaining assays for detection of Chlamydia pneumoniae in atherosclerotic arteries indicate cross-reactions with nonchlamydial plaque constituents.

Authors:  Vicky Y Hoymans; Johan M Bosmans; Dominique Ursi; Wim Martinet; Floris L Wuyts; Eric Van Marck; Martin Altwegg; Christiaan J Vrints; Margareta M Ieven
Journal:  J Clin Microbiol       Date:  2004-07       Impact factor: 5.948

Review 8.  Review and meta-analysis of epidemiological associations between low/moderate doses of ionizing radiation and circulatory disease risks, and their possible mechanisms.

Authors:  M P Little; E J Tawn; I Tzoulaki; R Wakeford; G Hildebrandt; F Paris; S Tapio; P Elliott
Journal:  Radiat Environ Biophys       Date:  2009-10-28       Impact factor: 1.925

9.  Antibody levels against Chlamydia pneumoniae and outcome of roxithromycin therapy in patients with acute myocardial infarction. Results from a sub-study of the randomised Antibiotic Therapy in Acute Myocardial Infarction (ANTIBIO) trial.

Authors:  U Burkhardt; R Zahn; U Höffler; K E Siegler; B Frilling; M Weber; M Gottwik; M Wehr; F Seidel; S Rosocha; U Tebbe; J Senges
Journal:  Z Kardiol       Date:  2004-09

10.  Potential increased risk of ischemic heart disease mortality with significant dose fractionation in the Canadian Fluoroscopy Cohort Study.

Authors:  Lydia B Zablotska; Mark P Little; R Jack Cornett
Journal:  Am J Epidemiol       Date:  2013-10-20       Impact factor: 4.897

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.